abilify depression seen ads hopefully read blog excellent series la times melissa healy advantage placebo nothing get particularly excited especially patients point view i mentioned previously two studies touted key opinion leaders supporting efficacy abilify depression suffered number problems germane post patient self report rating scales indicate significant advantage abilify either study well yet another abilify depression study cns spectrums guess still significant advantage placebo according patients three large studies abilify failed beat placebo according patients self report three trials basis massive marketing campaign fda approval abilify started also ran antipsychotic times changed bristol myers squibb ceo prophetically stated abilify approval treatment bipolar disorder approval underscores commitment delivering innovative solutions address unmet needs broad spectrum patients mental illness well families health care providers could easily stated approval underscores commitment rebranding unpopular antipsychotic swiss army knife broad spectrum psychotropic treats everything sun i get fda public believe akathisia inducing bottom feeder treat depression i loaded bwaah ha ha ha ha ok maybe actually say things broad spectrum comment literally right money ask pesky patients think might tell better damn sugar pill yes i aware rating scales abilify rated superior placebo i thinking patient self report depression consistently favorable abilify kidding calling antidepressant robert berman maurizio fava michael thase madhukar trivedi ren swanink robert mcquade william carson david adson leslie taylor james hazel ronald marcus aripiprazole augmentation major depressive disorder double blind placebo controlled study patients inadequate response antidepressants cns spectrums